Please ensure Javascript is enabled for purposes of website accessibility

More COVID Vaccines Should Become Available With This Major Strategy Change

By Keith Speights - Jan 22, 2021 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But it does come with one potential downside.

It's no secret that the rollouts of the COVID-19 vaccines developed by Moderna (MRNA -0.92%) and Pfizer (PFE 0.56%) with its partner BioNTech (BNTX 0.11%) haven't gone as well as hoped. Many Americans who want a vaccine haven't been able to get one yet. In this Motley Fool Live video recorded on Jan. 13, 2021, healthcare and cannabis bureau chief Corinne Cardina and writer Keith Speights discuss a major strategy change that should make more vaccines available more quickly.

Corinne Cardina: Another change in vaccination strategy has been around the doses that were being held back. Joe Biden, President-elect had said, when I come into office, we're going to stop holding back doses for that second dose that are in the freezer, which has been President Trump's taskforce strategy. Now, President Trump's strategy has come out and matched what Joe Biden said he would do.

Can you talk a little bit about why they were holding back doses? Is it OK to give out all the doses we have? Will there be second doses ready when people need them, if they do this?

Keith Speights: The original strategy, in some respects, makes sense. What the federal government was doing was they were saying, OK, everyone, needs to receive two doses. To ensure that they get their second dose, we're only going to ship out enough for people to get their first dose and hold back that second dose until closer to the time when individuals will need that second dose.

Like I said, from one respect that makes sense. It ensures that everyone gets, becomes fully dosed, fully vaccinated rather. The challenge there though is that that limits how many people can get their first dose if you're holding back the doses from being shipped.

What the incoming Biden administration said was, we'd like to go ahead and ship those doses out, get more people receiving that first dose. Like you said, Corinne, the Trump administration ultimately agreed that that's probably the best thing to do.

Like you mentioned, the downside is what happens if there are wrinkles and those second doses aren't available. I think that's just a risk that's worth taking though. At least thus far we're not seeing any significant issues with manufacturing the doses. There have been a few blips along the road, for sure. But there's nothing that would raise serious concerns at this point that those second doses wouldn't be available. But that is the trade-off with this change in strategy.

Corinne Cardina: Right. Some people involved said that if there were a problem with getting those second doses they could invoke the Defense Production Act, to get more doses made at a quicker speed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$53.71 (0.56%) $0.30
Moderna, Inc. Stock Quote
Moderna, Inc.
$130.85 (-0.92%) $-1.21
BioNTech SE Stock Quote
BioNTech SE
$154.67 (0.11%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.